Skip to content
The Nexus
DossierENTITY

AI drug-design

Coverage of AI drug-design in the Nexus archive.

Earliest in view: Jul 2 · 11:00 UTCMost recent: Jul 2 · 11:00 UTC
Co-mentioned in this coverage
Linda Shuperson1HSBCorganization1Chinaplace1United Statesplace1Biotech companiestopic1
Recent coverage
  • BUSINESSJul 2 · 11:00 UTCSCMP WORLD
    China AI drug-design deals swell as US scrutiny mounts

    Chinese AI-driven drug-design firms are securing global deals despite US scrutiny, with out-licensing deals reaching $75 billion in the first five months of 2026, up from zero before 2020.

AI drug-design · Dossier · The Nexus